EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, F-star Therapeutics's Enterprise Value is $133.62 Mil.
F-star Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 was $-37.91 Mil. Therefore, F-star Therapeutics's EV-to-FCF for today is -3.52.
The historical rank and industry rank for F-star Therapeutics's EV-to-FCF or its related term are showing as below:
FSTX'
s EV-to-FCF Range Over the Past 10 Years
Min: -4.92 Med: -2.18 Max: 0.27
Current: -3.52
During the past 3 years, the highest EV-to-FCF of F-star Therapeutics was 0.27. The lowest was -4.92. And the median was -2.18.
FSTX's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 6.365
vs FSTX: -3.52
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for F-star Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of F-star Therapeutics's EV-to-FCF
For the Biotechnology subindustry, F-star Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
F-star Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, F-star Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where F-star Therapeutics's EV-to-FCF falls into.
F-star Therapeutics's current Enterprise Value is $133.62 Mil.
F-star Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
F-star Therapeutics's PE Ratio for today is calculated as:
F-star Therapeutics's share price for today is $7.12.
F-star Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.820.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
F-star Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of F-star Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
F-star Therapeutics (F-star Therapeutics) Business Description
F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FSTX has been successfully added to your 